Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/8/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. David M. Kleinman MD MBA

Wrong Dr. David M. Kleinman MD MBA?

Chief Medical Officer

Company Description: AlterVista is managed solo by his creator, thanks to crowdsourcing and to a sustainable and adaptable structure and it keeps growing over and over. At the beginning...   more
Background

Employment History

  • President and Chief Executive Officer
    Eyeon Therapeutics
  • President and Co-founder
    Eyeon Therapeutics
  • Chief Executive Officer
    Eyeon Particle Sciences LLC
  • Associate Professor of Ophthalmology (Part Time)
    Flaum Eye Institute at the University of Rochester
  • Part-Time Associate Professor of Ophthalmology
    Flaum Eye Institute at the University of Rochester
  • Associate Professor and Retina Specialist
    Flaum Eye Institute at the University of Rochester
  • Assistant Professor of Ophthalmology
    Strong Memorial Hospital
  • Retinal Specialist
    Strong Memorial Hospital
  • Physician
    Strong Memorial Hospital
  • University of Rochester
  • Chief of Ophthalmology
    Denver Health

Education

  • M.D.
    The University of Rochester Eye Institute
  • M.B.A.
  • MD
  • MBA
  • medical degree with honors
    University of Colorado School of Medicine
  • M.D.
    University of Rochester Eye Institute - Donald Grover
34 Total References
Web References
David M. Kleinman, MD, MBA, ...
www.reviewofophthalmology.com, 8 Sept 2015 [cached]
David M. Kleinman, MD, MBA, Rocherster, N.Y., and David N. Zacks, MD, PhD, Ann Arbor, Mich.
...
Dr. Kleinman is a part-time associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester where he specializes in the medical and surgical care of patients with retinal disease. He has spent more than 10 years working in retinal pharmaceutical development and currently serves as the chief medical officer at ONL Therapeutics Inc.
David M. Kleinman, M.D., ...
www.onltherapeutics.com, 9 Dec 2014 [cached]
David M. Kleinman, M.D., M.B.A., Chief Medical Officer
Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery and more than ten years experience in venture creation and ophthalmic drug and device development. He currently serves as a part-time associated professor ophthalmology at the Flaum Eye Institute at the University of Rochester, where he specializes in the medical and surgical care of patients with retinal disease. David is the former chief of ophthalmology at Denver Health Medical Center, where he also served as an assistant professor of ophthalmology at the Rocky Mountain Lions Eye Institute.
In 2003, he helped found MacuSight, a venture capital backed retinal drug development company, where served as consulting medical director. In his role with MacuSight, David assisted in guiding the company through Series A financing, pre-clinical studies, initial investigational new drug (IND) submission, and Phase I/II clinical development. MacuSight's assets were acquired by Santen in 2010. He holds a bachelor's degree from Brown University, an MBA from the Simon School of Business, and an M.D. with honors from the University of Colorado School of Medicine.
David Kleinman, M.D. - University of Rochester Eye Institute - Retina
www.stronghealth.org, 10 Oct 2008 [cached]
David Kleinman, M.D., M.B.A.
...
David M. Kleinman, MD, MBA, FACS is a board certified ophthalmologist with fellowship training in vitreoretinal surgery.Dr. Kleinman received his medical degree with honors and completed a subsequent residency in ophthalmology at the University of Colorado School of Medicine.He then recieved additional training through a fellowship in vitreoretinal surgery at the University of Toronto School of Medicine.Dr. Kleinman is the former Chief of Ophthalmology at Denver Health Medical Center in Denver, Colorado where he also served as Director of Ophthalmic Trauma Services and Assistant Professor of Ophthalmology at the Rocky Mountain Lions Eye Institute.
Besides attending to his clinical practice at the University of Rochester Eye Institute, Dr. Kleinman is President and Co-founder of Eyeon Therapeutics, Inc. a start-up firm developing new treatments for eye diseases.He also serves as a consultant to both large and small ophthalmic pharmaceutical and device companies nationally.
...
Dr. Kleinman's research involves the pharmaceutical treatment of diabetic retinopathy and age related macular degeneration.He has made numerous contributions to clinical and research publications in national and international journals of ophthalmology, and has made presentations throughout the world.In addition, he participated as a surgeon for the Himalayan Cataract Project and served as a staff ophthalmologist for Project ORBIS International, Inc.
Dr. Kleinman sees patients at our Strong Memorial Hospital offices.
Dr. David M. Kleinman, an ...
www.dallasymca.org, 14 Mar 2011 [cached]
Dr. David M. Kleinman, an associate professor and retina specialist with the Flaum Eye Institute at the University of Rochester in Rochester, N.Y., described the findings as "unsurprising, but very helpful."
"All scientists are going to say they need more research," he noted.
The ISTA deal comes as the ...
www.democratandchronicle.com [cached]
The ISTA deal comes as the ophthalmic pharmaceutical market - expected to reach $17 billion globally by 2015, according to Global Industry Analysts Inc. estimates - is growing due to aging populations and the eye problems that come with age, said Dr. David M. Kleinman, associate professor of ophthalmology at the University of Rochester Medical Center and CEO/co-founder of Eyeon Therapeutics Inc.
Before the B+L deal, Valeant Pharmaceuticals International Inc. unsuccessfully sought to purchase ISTA. Last month it purchased the ophthalmic biotechnology company Eyetech Inc. Merck & Co. in 2011 purchased Inspire Pharmaceuticals Inc., which specialized in ophthalmic products. Glaxo-SmithKline and other global pharmaceutical companies continue to look at ophthalmology as good opportunities for meaningful growth, said Kleinman.
B+L earlier this month said it was starting a phase III clinical trial for a pharmaceutical being developed for treatment of glaucoma or ocular hypertension. The drug being tested was developed by French pharmaceutical company NicOx SA, which in 2010 licensed it to B+L.
"You see the large eye companies focusing on pharma acquisitions and licensing because everybody knows there are good treatments for ophthalmic diseases with pharmaceuticals," said Kleinman, who has done some consulting work for B+L.
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304